Live Breaking News & Updates on Rituximab

Stay updated with breaking news from Rituximab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Much-Improved Outcomes for Follicular Lymphoma Transformed to DLBCL in the Rituximab Era, Study Finds

Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular lymphoma, patient survival has increased significantly since the introduction of rituximab about 2 decades ago. ....

Image Credit , Cancer Medicine , End Results , Follicular Lymphoma ,

Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes

A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
....

B Cell Lymphoma , Image Credit , Doxorubicin Hydrochloride ,

Observational Study Shows Frontline Ibrutinib With/Without Rituximab Is Safe and Effective in Low-Risk Mantle Cell Lymphoma

Ibrutinib with or without rituximab was effective and tolerable in patients with previously untreated, low-risk mantle cell lymphoma. ....

United Kingdom , Ibrutinib Imbruvica , Ann Tivey , International Prognostic Score Index , University Of Manchester , Prognostic Score Index , Mantle Cell Lymphoma ,

Sequencing Therapies in the Third-Line and Beyond Setting for MCL

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL. ....

Recent Updates , Follicular Lymphoma , Mantle Cell Lymphoma , Beyond Setting , Sequencing Therapy , Brexu Cel , Btk Inhibitor , Cart Cell Therapy , Liso Cel ,

First-line rituximab for pemphigus associated with long-term complete remission rates

1. Patients with pemphigus treated with first-line rituximab showed sustained complete remission rates without corticosteroids for up to 7 years post-treatment 2. High-risk patients for pemphigus relapse could be assessed with enzyme-linked immunosorbent assay (ELISA) values of anit-Dsg antibodies. Evidence Rating Level: 1 (Excellent) Study Rundown: Pemphigus is a life-threatening rare autoimmune bullous disease affecting ....

Rating Level ,